Results 81 to 90 of about 5,903 (227)

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

The Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas, Debbie J. Otto, Daniel Stratton, Katja Rietdorf, Daniel M. Johnson, Calum J. McMullen   +5 more
wiley   +1 more source

Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics [PDF]

, 2019
Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are among the most frequently prescribed anticancer drugs. They are inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD).
Lunenburg, C.A.T.C.
core  

Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion

Nature Communications, 2020
The gut microbiota can alter the effects of anticancer fluoropyrimidines such as 5-fluorodeoxyuridine (FUdR) in the model organism C. elegans. Here, the authors show that these effects are further affected by diet, and dietary thymidine and serine ...
Wenfan Ke, James A. Saba, Cong-Hui Yao, Michael A. Hilzendeger, Anna Drangowska-Way, Chintan Joshi, Vinod K. Mony, Shawna B. Benjamin, Sisi Zhang, Jason Locasale, Gary J. Patti, Nathan Lewis, Eyleen J. O’Rourke   +12 more
doaj   +1 more source

Implementation and feasibility of DPYD-guided fluoropyrimidine use in a gastrointestinal oncology clinic at an academic medical center

Frontiers in Oncology
IntroductionGenetic variation in DPYD can result in reduced fluoropyrimidine (FP) metabolism and increased risk of severe toxicity. This DPYD test implementation pilot aimed to establish a feasible workflow for DPYD ordering sample collection and FP dose
Madeline L. Norris, Madeline L. Norris, Khoa A. Nguyen, Khoa A. Nguyen, Emily J. Cicali, Emily J. Cicali, Wandyeind Marquez Moyeno, Je-Won J. Hong, Katherine Vogel Anderson, Tim Jang, Tim Jang, Gahyun Gim, Gahyun Gim, Kathleen Sullivan, Alexandra Kennan, Petr Starostik, Thomas J. George, Thomas J. George, David L. DeRemer, David L. DeRemer, David L. DeRemer, Larisa H. Cavallari, Larisa H. Cavallari, Julio D. Duarte, Julio D. Duarte   +24 more
doaj   +1 more source

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

Therapeutic Advances in Medical Oncology, 2019
Background: Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) is a novel treatment option for gemcitabine-pretreated metastatic pancreatic adenocarcinoma (PAC) patients, but real-world evidence is rare.
Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager   +4 more
doaj   +1 more source

CLDN18.2 in pancreatic ductal adenocarcinoma: Biomarker assessment, spatial heterogeneity and therapeutic modality selection

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan, Zhexin Zhang, Jiaxin Wang, Roland Andersson, Daniel Ansari, Jinfei Chen   +5 more
wiley   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Volker Heinemann, Paulo M. Hoff, Heinemann, Volker, Hoff, Paulo M.   +3 more
core   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, Volume 16, Issue 9, Page 1813-1824, September 2026.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

Takotsubo Syndrome and Cancer: Pathophysiological Links and Clinical Perspectives

Biomedicines
Takotsubo syndrome (TTS) is an acute, reversible cardiomyopathy that clinically mimics acute coronary syndrome in the absence of obstructive coronary artery disease.
Adriana Correra, Alfredo Mauriello, Anna Chiara Maratea, Celeste Fonderico, Matilde Di Peppo, Vincenzo Russo, Antonello D’Andrea, Giovanni Esposito, Natale Daniele Brunetti   +8 more
doaj   +1 more source